Treatment of faecal incontinence using allogeneic-adipose-derived mesenchymal stem cells: a study protocol for a pilot randomised controlled trial

Eun Jung Park, Jeonghyun Kang, Seung Hyuk Baik, Eun Jung Park, Jeonghyun Kang, Seung Hyuk Baik

Abstract

Introduction: Faecal incontinence is a distressing condition with recurrent uncontrolled passage of faecal material. Although faecal incontinence may cause psychological depression and social isolation, previous treatments have been limited. Recently, regenerative treatment has been developed using mesenchymal stem cells. Especially, there are possibilities that adipose-tissue-derived stem cells can be effective to treat a degenerated anal sphincter that is causing faecal incontinence. Therefore, this study aimed to investigate the safety and efficacy of using allogeneic-adipose-derived mesenchymal stem cells in the treatment of the anal sphincter of patients with faecal incontinence.

Methods and analysis: This study is a randomised, prospective, dose escalation, placebo-controlled, single-blinded, single-centre trial with two parallel groups. The safety test is performed by an injection of allogeneic-adipose-derived mesenchymal stem cells (ALLO-ASCs) into the anal sphincter with dose escalation (3 × 10(7), 6 × 10(7) and 9 × 10(7) cells, sequentially). After confirming the safety of the stem cells, an efficacy test is performed by this dose in the experimental group. The experimental group will receive ALLO-ASCs mixed with fibrin glue into the anal sphincter, and the placebo group will receive 0.9% normal saline injection mixed with fibrin glue. The primary end point is to assess the safety of ALLO-ASCs after the injection into the anal sphincter, and the secondary end point is to compare the efficacy of ALLO-ASC injection with fibrin glue in patients with faecal incontinence.

Ethics and dissemination: The study protocol was approved by the Ministry of Food and Drug Safety and the Ministry of Health & Welfare, in the Republic of Korea. The informed consent form was approved by the institutional review board of Gangnam Severance Hospital (IRB approval number 3-2014-0271). Dissemination of the results will be presented at a conference and in peer-reviewed publications.

Trial registration number: NCT02384499; Pre-results.

Keywords: adipose-derived mesenchymal stem cell; fecal incontinence; mesenchymal stem cell; stem cell.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Trial schema.
Figure 2
Figure 2
The site of ALLO-ASC injection in the anal sphincter. IAS, internal anal sphincter; EAS, external anal sphincter. Black arrow, the direction of the ALLO-ASC injection.

References

    1. Whitehead WE, Wald A, Diamant NE et al. . Functional disorders of the anus and rectum. Gut 1999;45(Suppl 2):II55–9.
    1. Bharucha AE, Dunivan G, Goode PS et al. . Epidemiology, pathophysiology, and classification of fecal incontinence: state of the science summary for The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop. Am J Gastroenterol 2015;110:127–36. 10.1038/ajg.2014.396
    1. Johanson JF, Lafferty J. Epidemiology of fecal incontinence: the silent affliction. Am J Gastroenterol 1996;91:33–6.
    1. Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum 1993;36:77–97. 10.1007/BF02050307
    1. Engel BT, Nikoomanesh P, Schuster MM. Operant conditioning of rectosphincteric responses in the treatment of fecal incontinence. N Engl J Med 1974;290:646–9. 10.1056/NEJM197403212901202
    1. Bliss DZ, Jung HJ, Savik K et al. . Supplementation with dietary fiber improves fecal incontinence. Nurs Res 2001;50:203–13. 10.1097/00006199-200107000-00004
    1. Matzel KE, Stadelmaier U, Hohenfellner M et al. . Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence. Lancet 1995;346:1124–7. 10.1016/S0140-6736(95)91799-3
    1. Kang SB, Lee HN, Lee JY et al. . Sphincter contractility after muscle-derived stem cells autograft into the cryoinjured anal sphincters of rats. Dis Colon Rectum 2008;51:1367–73. 10.1007/s10350-008-9360-y
    1. Frudinger A, Kolle D, Schwaiger W et al. . Muscle-derived cell injection to treat anal incontinence due to obstetric trauma: pilot study with 1 year follow-up. Gut 2010;59:55–61. 10.1136/gut.2009.181347
    1. Romaniszyn M, Rozwadowska N, Nowak M et al. . Successful implantation of autologous muscle-derived stem cells in treatment of faecal incontinence due to external sphincter rupture. Int J Colorectal Dis 2013;28:1035–6. 10.1007/s00384-013-1692-y
    1. Frudinger A, Pfeifer J, Paede J et al. . Autologous skeletal-muscle-derived cell injection for anal incontinence due to obstetric trauma: a 5-year follow-up of an initial study of 10 patients. Colorectal Dis 2015;17:794–801. 10.1111/codi.12947
    1. Cho YB, Lee WY, Park KJ et al. . Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study. Cell Transplant 2013;22:279–85. 10.3727/096368912X656045
    1. Lee WY, Park KJ, Cho YB et al. . Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula. Stem Cells 2013;31:2575–81. 10.1002/stem.1357
    1. Puissant B, Barreau C, Bourin P et al. . Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005;129:118–29. 10.1111/j.1365-2141.2005.05409.x
    1. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708–20. 10.1093/jnci/djp079
    1. Rockwood TH, Church JM, Fleshman JW et al. . Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum 2000;43:9–16; discussion 16–17 10.1007/BF02237236
    1. Kim I, Lee SK, Yoon JI et al. . Fibrin glue improves the therapeutic effect of MSCs by sustaining survival and paracrine function. Tissue Eng Part A 2013;19:2373–81. 10.1089/ten.TEA.2012.0665
    1. Guo HD, Wang HJ, Tan YZ et al. . Transplantation of marrow-derived cardiac stem cells carried in fibrin improves cardiac function after myocardial infarction. Tissue Eng Part A 2011;17:45–58. 10.1089/ten.TEA.2010.0124
    1. Xu X, Menees SB, Zochowski MK et al. . Economic cost of fecal incontinence. Dis Colon Rectum 2012;55:586–98. 10.1097/DCR.0b013e31823dfd6d
    1. Wald A. Clinical practice. Fecal incontinence in adults. N Engl J Med 2007;356:1648–55. 10.1056/NEJMcp067041
    1. Lorenzi B, Pessina F, Lorenzoni P et al. . Treatment of experimental injury of anal sphincters with primary surgical repair and injection of bone marrow-derived mesenchymal stem cells. Dis Colon Rectum 2008;51:411–20. 10.1007/s10350-007-9153-8
    1. Mizuno H, Hyakusoku H. Mesengenic potential and future clinical perspective of human processed lipoaspirate cells. J Nippon Med Sch 2003;70:300–6. 10.1272/jnms.70.300
    1. Garcia-Olmo D, Garcia-Arranz M, Herreros D et al. . A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005;48:1416–23. 10.1007/s10350-005-0052-6
    1. Garcia-Olmo D, Herreros D, Pascual I et al. . Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009;52:79–86. 10.1007/DCR.0b013e3181973487
    1. Wang J, Liao L, Tan J. Mesenchymal-stem-cell-based experimental and clinical trials: current status and open questions. Expert Opin Biol Ther 2011;11:893–909. 10.1517/14712598.2011.574119
    1. Rehman J, Traktuev D, Li J et al. . Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004;109:1292–8. 10.1161/01.CIR.0000121425.42966.F1
    1. Chen L, Tredget EE, Wu PY et al. . Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 2008;3:e1886 10.1371/journal.pone.0001886
    1. Hare JM, Fishman JE, Gerstenblith G et al. . Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012;308:2369–79. 10.1001/jama.2012.25321
    1. Huang XP, Sun Z, Miyagi Y et al. . Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010;122:2419–29. 10.1161/CIRCULATIONAHA.110.955971
    1. Le Blanc K, Tammik C, Rosendahl K et al. . HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890–6. 10.1016/S0301-472X(03)00110-3
    1. McIntosh K, Zvonic S, Garrett S et al. . The immunogenicity of human adipose-derived cells: temporal changes in vitro. Stem Cells 2006;24:1246–53. 10.1634/stemcells.2005-0235
    1. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726–36. 10.1038/nri2395
    1. Rubio D, Garcia-Castro J, Martin MC et al. . Spontaneous human adult stem cell transformation. Cancer Res 2005;65:3035–9. 10.1158/0008-5472.CAN-04-4194

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi